Decoy Therapeutics is trading 6.4% down at $3.50 in pre-market, extending a sharp multi-day slide that accelerated on July 27, 2026, despite a lack of company-specific news.
- The decline appears driven by technical selling, sentiment, or liquidity rather than a defined fundamental event.
- There are currently no fresh earnings reports or major regulatory developments tied to the continued weakness.